Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

Authors Jones PW

Received 28 October 2014

Accepted for publication 10 February 2015

Published 26 March 2015 Volume 2015:10(1) Pages 677—687

DOI https://doi.org/10.2147/COPD.S76520

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Paul W Jones

Institute for Infection and Immunity, Faculty of Respiratory Medicine, St George’s, University of London, London, UK

Abstract: Three long-acting muscarinic antagonists (LAMAs) are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. The first LAMA, tiotropium, has been widely used over the last decade as a once-daily maintenance therapy in stable COPD to improve patients’ health-related quality of life and to reduce the risk of exacerbations. Administered via the HandiHaler® device, it is safe and well tolerated. Another new once-daily LAMA, glycopyrronium, has also been shown to improve health status and reduce exacerbations, and is well tolerated. The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. In the pivotal Phase III clinical trials, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks. In continuation studies, these improvements were sustained for up to 52 weeks. Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program – the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events. While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.

Keywords: aclidinium bromide, anticholinergic, long-acting muscarinic antagonist, chronic obstructive pulmonary disease, multidose dry powder inhaler
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

COPD: the patient perspective

Jones PW, Watz H, Wouters EFM, Cazzola M

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:13-20

Published Date: 19 February 2016

A bibliometric analysis of the 100 most influential papers on COPD

Gu WC, Yuan YP, Yang H, Qi GS, Jin XY, Yan J

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:667-676

Published Date: 25 March 2015

COPD and its association with smoking in the Mainland China: a cross-sectional analysis of 0.5 million men and women from ten diverse areas

Kurmi OP, Li L, Wang J, Millwood IY, Chen J, Collins R, Guo Y, Bian Z, Li J, Chen B, Xie K, Jia W, Gao Y, Peto R, Chen Z

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:655-665

Published Date: 20 March 2015

Caregivers’ burden in patients with COPD

Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:347-356

Published Date: 12 February 2015

Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD

Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:283-291

Published Date: 4 February 2015